Spryte Medical

What Spryte Medical does

Spryte Medical is a privately held medical device company developing the nOCT (neuro Optical Coherence Tomography) Imaging System, a catheter-based imaging platform designed to perform high-resolution intravascular imaging inside the brain's arteries for the first time. The system is composed of three integrated components: an AI-enabled console, an optical module, and a miniaturized fiber-optic neuroendovascular probe engineered to navigate the small, tortuous vasculature of the brain using a standard neurovascular wire workflow. The platform produces cross-sectional images of biological tissue with micro-meter resolution using backscattered light, allowing neurointerventionalists to visualize structures past the arterial lumen, through the vessel wall, and into the perivascular space — capabilities that angiography and cone beam CT cannot deliver.

The company is targeting treatment of brain aneurysms, ischemic stroke, and atherosclerotic intracranial disease, with primary customers being neurointerventionalists and academic medical centers performing endovascular neurovascular procedures. Spryte is pre-commercial: the nOCT Imaging System is under development and not yet available for sale, and the company is pursuing FDA marketing authorization through the INSYTE US Pivotal Trial, which completed enrollment of 65 subjects across 8 centers in 3 countries in July 2026. The company has received FDA Breakthrough Device Designation and holds 17 granted patents across the United States, Europe, Japan, and China. Its go-to-market is planned as direct hospital sales of capital equipment combined with recurring consumable imaging probe revenue, with no public pricing disclosed ahead of FDA clearance. KOL partnerships — including Dr. Vitor Mendes Pereira at St. Michael's Hospital Toronto and Dr. Matthew Gounis — have supported first-in-human work published in Science Translational Medicine and a comprehensive review in J NeuroIntervent Surg.

Name

Spryte Medical

Legal name

Spryte Medical, LLC

Website

https://sprytemedical.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Spryte Medical is a Bedford, MA-based pre-commercial medical device company developing the AI-enabled nOCT Imaging System, a fiber-optic intravascular probe for high-resolution imaging inside the brain's arteries during treatment of aneurysms, ischemic stroke, and intracranial vascular disease.

Ownership category

akta.pro rank

Product category

Neurovascular Intravascular Imaging Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)

akta.pro secondary industry

Medical Imaging AI (HDAAAEAH)

Keywords

• Intravascular imaging systems
• Neurovascular medical devices
• Optical coherence tomography
• Cerebrovascular imaging
• Neurointerventional imaging

Headquarters

HQ city

Bedford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Once FDA marketing authorization is obtained, the company plans to commercialize its nOCT Imaging System through direct sales to hospitals and neurointerventional centers. The revenue model will likely involve capital equipment sales combined with consumable imaging probes.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Spryte Medical is developing the nOCT (neuro Optical Coherence Tomography) Imaging System, an AI-enabled medical imaging platform designed for high-resolution intravascular imaging inside the brain. The system consists of an AI-powered console, an optical module, and a fiber-optic neuroendovascular probe that navigates the highly tortuous vasculature of the brain, enabling neurointerventionalists to visualize anatomic structures, disease, and device-tissue interactions at micro-meter resolution. The product is under development and has not yet received FDA marketing authorization.

Product overview

Spryte Medical offers a single core product: the nOCT (neuro Optical Coherence Tomography) Imaging System. This is a proprietary AI-enabled medical imaging platform consisting of three integrated components: an AI-powered console, an optical module, and a fiber-optic neuroendovascular probe. The system brings high-resolution intravascular optical imaging inside the brain for the first time, enabling neurointerventionalists to visualize anatomic structures, diseases, and therapies at micro-meter resolution. The nOCT Imaging System is designed for use during endovascular treatment of intracranial aneurysms and other neurovascular procedures. The product is currently under development and has not yet received FDA marketing authorization.

Differentiator

Problem solved

Functional benefit

Products and services

• Spryte nOCT Imaging System AI-enabled neuro Optical Coherence Tomography imaging platform comprising an AI-powered console, an optical module, and a miniaturized fiber-optic neuroendovascular probe. Designed for use by neurointerventionalists during endovascular treatment of brain aneurysms, ischemic stroke, and atherosclerotic intracranial disease, producing cross-sectional intravascular images of biological tissue with micro-meter resolution. Currently under development and not available for sale.

Quantifiable outcome

• >10x resolution compared to current imaging systems

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Emerging players

• Conavi Medical: Conavi Medical is a Canadian company developing intravascular imaging systems (both IVUS and OCT) for cardiovascular applications. As a smaller, focused intravascular imaging player, it is a direct technology analog with comparable miniaturization and optical engineering challenges.
• Terumo (Cardiovascular): Terumo has developed OCT and other intravascular imaging technologies for cardiovascular applications. It is a relevant technology peer given shared OCT expertise and could be a strategic partner or competitor as the technology expands into neurovascular indications.
• Viz.ai: Viz.ai applies AI to neurovascular workflow, including stroke triage and imaging analysis. While focused on software rather than intravascular hardware, it shares the AI-enabled neurovascular imaging thesis and similar clinical customer base at comprehensive stroke centers.
• RapidAI: RapidAI provides AI-based imaging analysis for stroke and other neurovascular conditions. It is comparable as a software-and-AI peer targeting the same neurointerventionalist customers, and signals the broader shift toward AI-augmented neuroimaging that supports Spryte's positioning.
• InspireMD: InspireMD is a smaller neurovascular device company developing carotid and cerebral embolic protection stents. It is a relevant emerging peer in the pre-commercial and early-commercial neurovascular space, with comparable regulatory pathway dynamics and customer base.

Broad incumbents

• Abbott (Vascular): Abbott owns the market-leading intravascular OCT platform (Dragonfly OPTIS) for coronary applications. The OCT technology stack is directly comparable to Spryte's, making Abbott the most relevant technology analog and a likely strategic interest in a neurovascular extension of intravascular OCT.
• Medtronic (Neurovascular): Medtronic's Neurovascular business supplies a broad portfolio of coils, flow diverters, and access devices used in the same aneurysm and stroke procedures where Spryte's nOCT would be deployed. As a broad incumbent, it competes for hospital budgets and could integrate nOCT as a complementary visualization tool.
• Stryker (Neurovascular): Stryker's Neurovascular division (including acquired assets from Stryker/Wright/Covidien) supplies coils, stents, and access devices for neurovascular procedures. It serves the same hospital neurointerventional suites and represents both a future customer and a potential acquirer of Spryte's imaging platform.

Direct peers

• Penumbra: Penumbra is a leading neurovascular device company with a portfolio of stroke and aneurysm treatment products. It is the most direct strategic peer: an established neurovascular franchise that would be a natural commercial channel and potential acquirer of Spryte's complementary intravascular imaging technology.

Regional players

• MicroPort NeuroTech: MicroPort NeuroTech is a leading neurovascular device company in China, supplying flow diverters and other neurovascular implants. It is a geographical and product peer that serves many of the same KOLs and hospitals referenced in Spryte's INSYTE trial.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/spryte-medical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spryte Medical